title: Effects of transdermal nitroglycerin on left ventricular function after acute myocardial infarction.
abstract: Progressive left ventricular dysfunction in acute myocardial infarction patients is associated with a poor prognosis. It has been shown that some therapeutic measures which have the potential for limiting the infarct size and preserving ventricular function, are also able to reduce the incidence of congestive heart and improve survival. The aim of this protocol was to assess the effects of transdermal nitroglycerin administered within 72 hours after the onset of acute myocardial infarction and for the following 6 months, on left ventricular function. A total of 98 consecutive acute myocardial infarction patients were randomly allocated, within 72 hours of onset of symptoms, to a double-blind 6-month-therapy with either 10 mg/24 hour transdermal nitroglycerin or placebo. Patients underwent two-dimensional echocardiography at entry, after 2 weeks, 3 months and 6 months. In the nitroglycerin group, end-diastolic volume increased during the follow-up (+6.7%, p < 0.05) while end-systolic volume remained nearly unchanged; ejection fraction and stroke volume increased progressively (+6.3%, p < 0.05, +14.2%, p < 0.05, respectively) and a important reduction of percent of dyssynergic segments was present (-19.2%, p < 0.005). In the placebo group end-diastolic volume and end-systolic volume slightly increased during the follow-up (+2% and +4.9% respectively); ejection fraction and stroke volume remained nearly unchanged during the study; percent of dyssynergic segments showed an important decrease after 2 weeks and 6 months (-21.3%, p < 0.005). A clinically relevant increase (> 20%) in ejection fraction was present more frequently in the nitroglycerin than in the placebo group (p < 0.001). In conclusion, the early (within 72 hours) and prolonged (6 months) administration of transdermal nitroglycerin in acute myocardial infarction improves ejection fraction and stroke volume but does not modify ventricular remodeling.
authors.affiliation: Divisione di Cardiologia, Ospedale Umberto I, Mestre-Venezin, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Di Pede
authors.forename: P D
authors.initials: PD
authors.lastname: Pucci
authors.forename: G
authors.initials: G
authors.lastname: Zuin
authors.forename: G P
authors.initials: GP
authors.lastname: Cerisano
authors.forename: B
authors.initials: B
authors.lastname: De Piccoli
authors.forename: E
authors.initials: E
authors.lastname: Taddeucci
authors.forename: G
authors.initials: G
authors.lastname: Turiano
authors.forename: R
authors.initials: R
authors.lastname: Sabia
authors.forename: E
authors.initials: E
authors.lastname: Piccolo
authors.forename: P F
authors.initials: PF
authors.lastname: Fazzini
mesh_terms: D000208:Acute Disease; D000279:Administration, Cutaneous; D004311:Double-Blind Method; D004452:Echocardiography; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D005996:Nitroglycerin / Q000008:administration & dosage* / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D016277:Ventricular Function, Left / Q000187:drug effects*
chemical_list: D014665:Vasodilator Agents; D005996:Nitroglycerin